Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 1, 1996, Pages 54-61

  Neuvonen, Pertti J ^a   Jalava, Kirsi Maija ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DRUG METABOLITE; ITRACONAZOLE; MEVINOLIN; MEVINOLINIC ACID; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MYOPATHY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029758869     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90167-8     Document Type: Article

References (23)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results. Arch Intern Med 1991;151:43-9.
3. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J-34J.
4. Norman DJ, Illingworth DR, Murson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin [letter]. N Engl J Med 1988;318:46-7.
5. Marinella MA. More on lovastatin [letter]. West J Med 1995;162:176-7.
6. Smith PF, Eydelloth RS, Grossman SJ, et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991;257:1225-35.
7. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993;65:410-3.
8. Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP. Biotransformation of lovastatin; IV: identification of cytochrome P-450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991;290:355-61.
9. Gascon MP, Dayer P. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 1991;41:573-8.
10. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55;481-5.
11. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7.
12. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
13. Stubbs RJ, Schwartz M, Bayne WF. Determination of mevinolin and mevinolic acid in plasma and bile by reversed-phase high-performance liquid chromatography. J Chromatogr 1986;383:438-43.
14. Woestenborgshs R, Lorreyne W, Heykants J. Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. J Chromatogr 1987;413:332-7.
15. Heykants J, Van-Peer A, Van-de-Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989;32(suppl 1):67-87.
16. Dollery C, editor. Therapeutic drugs; vol 2. Edinburgh: Churchill Livingstone, 1991:L66-71.
17. Honig PK, Wortham DC, Zamani K, et al. Terfenadineketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-8.
18. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen PJ. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993;45:191-3.
19. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole [letter]. New Engl J Med 1995;333:664-5.
20. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994;37:221-5.
21. Bailey DG, Arnold MO, Strong A, Munoz C, Spence JD. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 1993; 54:589-94.
22. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995;58:127-31.
23. Vickers S, Duncan CA, Vyas KP, et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990;18: 476-83.